| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Royal Cancer Hospital, London
This excerpt was created in the absence of an abstract.
R48 is the first aromatic nitrogen mustard to be given orally which has been shown to be active in the reticuloses. Satisfactory remissions were obtained in only two of 11 cases of generalised Hodgkin's disease lasting 1 year and 6 months respectively. In lymphosarcoma and lymphatic leukæmia considerable effects were observed only in the most chronic cases, and were considered to be of no clinical importance.
R48 is less active than nitrogen mustard; it acts more slowly and remissions are less frequent, less complete, and of shorter duration than those induced by nitrogen mustard.
The one advantage of R48, other than its administration by mouth, is that it does not cause nausea and vomiting. Its main interest is that it is the first active member of a series which may yet yield a more satisfactory compound.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |